kristoff@GENBANK.BIO.NET (Dave Kristofferson) (06/28/90)
NOTE: The NIH Guide may be split into more than one mail message to
avoid truncation during e-mail distribution. The first message always
begins with the RFP/RFA summary sections followed by the appended
texts of the full RFP/RFAs.
----------------------------------------------------------------------
NIH GUIDE - Vol. 19, No. 24, June 29, 1990
NOTICES OF AVAILABILITY (RFPs AND RFAs)
CENTRAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE CLINICAL TRIALS (RFP) ........ 1
National Institute of Allergy and Infectious Diseases (84/117)
Index: ALLERGY, INFECTIOUS DISEASES
DCBDC SMALL RESEARCH GRANTS ON ANIMAL MODELS OF SOLID TUMORS
(RFA CA-90-18) .......................................(120/212, 324/662)..... 1
National Cancer Institute
Index: CANCER
ONGOING PROGRAM ANNOUNCEMENTS
NIMH FUNCTIONAL BRAIN IMAGING CENTERS FOR THE STUDY OF MENTAL
DISORDER (PA-90-18) ..................................(218/265).............. 2
National Institute on Mental Health
Index: MENTAL HEALTH
NOTICES OF AVAILABILITY (RFPs AND RFAs)
CENTRAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE CLINICAL TRIALS
RFP AVAILABLE: RFP-NIH-NIAID-DAIDS-91-13
P.T. 34; K.W. 0715008, 0740075, 0710070, 0780010, 0755010
National Institute of Allergy and Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID), NIH, has a
requirement to perform routine and innovative immunologic and virologic assays
to support AIDS vaccine trials undertaken by the NIAID AIDS Vaccine Clinical
Trials Network. This NIAID-sponsored project will take approximately five (5)
years to complete. A cost-reimbursement contract is anticipated, and one (1)
award will be made.
This is an announcement for an anticipated Request for Proposal (RFP).
RFP-NIH-NIAID-DAIDS-91-13 shall be issued on or about July 12, 1990, with a
closing date tentatively set for September 12, 1990.
Requests for the RFP should be directed in writing to:
Ms. Jacqueline Johnson
Contract Management Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Control Data Building, Room 222P
6003 Executive Blvd.
Bethesda, MD 20892
To receive a copy of the RFP, please supply this office with two (2)
self-addressed labels. All responsible sources may submit a proposal which
will be considered.
This advertisement does not commit the Government to award a contract.
DCBDC SMALL RESEARCH GRANTS ON ANIMAL MODELS OF SOLID TUMORS
RFA AVAILABLE: CA-90-18
P.T. 34; K.W. 0715035, 0755020, 0710070
National Cancer Institute
Letter of Intent Receipt Date: September 1, 1990
Application Receipt Date: October 10, 1990
INTRODUCTION
The Cancer Immunology Branch of the Division of Cancer Biology, Diagnosis, and
Centers (DCBDC) of the National Cancer Institute (NCI) invites applications
for small grants to develop and establish animal models of solid tumors of
non-hemopoietic origin to improve our understanding of the complexities of the
human immune response to these tumors. Models are sought which demonstrate
similar biological characteristics to human cancer, and which could be used in
future studies to analyze the immunobiology of host-tumor interactions. The
present Request for Applications (RFA) announcement is for a single
solicitation with a specified deadline (October 10, 1990) for receipt of
applications and September 1, 1990, for receipt of letters of intent.
RESEARCH GOALS AND SCOPE
The goal of this initiative is to provide funds for the development of new, or
further characterization of existing, animal models of solid tumors of
non-hematopoietic origin which are relevant to human cancer. The initiative
is not limited to small laboratory animals (e.g., mice); however, appropriate
reagents, such as antibodies for cellular identification, must be available
for the immunologic study of any animal model proposed.
The scope of this initiative may comprise the use of transgenic animals, mice
with the severe combined immunodeficiency (SCID) defect, spontaneously arising
tumors, transplantable tumors from the site of origin to the same site within
the recipient, or other tumor systems developed by the applicant. Tumors
induced by chemicals, viruses or radiation will be considered if the tumor
type exhibits characteristics analogous to a human tumor. Animal models which
NIH GUIDE - Vol. 19, No. 24, June 29, 1990 - Page 1
utilize congenitally athymic (nude) mice where human tumors are injected
subcutaneously into these mice primarily for maintaining the tumor will be
excluded from review, and those applications will be returned to the
applicant.
MECHANISM OF SUPPORT
Support of this program will be through the National Institutes of Health
(NIH) grant-in-aid. Applicants will be responsible for the planning,
direction, and execution of the proposed project. Except as otherwise stated
in this RFA, awards will be administered under PHS policy as stated in the
Public Health Service Grants Policy statement, DHHS Publication No. (OASH)
82-50,000, revised January 1, 1987. This RFA is a one-time solicitation.
The small grants (R03) mechanism provides research support specifically
limited in time and amount for studies in categorical program areas. Small
grants provide flexibility for initiating studies, which are generally for
preliminary short-term projects and are non-renewable. Furthermore, the time
interval from application to funding is shortened under the R03 mechanism,
thus allowing new ideas to be investigated or pursued in a more expeditious
manner.
Approximately $700,000 in total costs per year for three years will be
committed specifically to fund applications which are submitted in response to
this RFA. The total direct costs per application may not exceed $50,000 per
year. It is anticipated that approximately 10 awards will be made. This
funding level is dependent on the receipt of a sufficient number of
applications of high scientific merit. The total project period for
applications submitted in response to this RFA should be at least one (1) year
and may not exceed two (2) years. The earliest feasible start date for awards
will be April 1, 1991. Although this program is provided for in the financial
plans of the NCI, the award of grants pursuant to this RFA is also contingent
upon the availability of funds for this purpose.
INQUIRIES
Prospective applicants are strongly encouraged to discuss their ideas with Dr.
John Finerty (see below) to determine whether they fit the definition and
guidelines of this announcement. The Program Director welcomes the
opportunity to discuss this RFA with potential applicants. For further
information, prospective applicants should contact:
Dr. John F. Finerty
Program Director
Cancer Immunology Branch
National Cancer Institute
National Institutes of Health
Executive Plaza South, Room 634
6120 Executive Boulevard
Rockville, MD 20892
Telephone: (30l) 496-78l5
FAX: 30l-496-8656
ONGOING PROGRAM ANNOUNCEMENTS
NIMH FUNCTIONAL BRAIN IMAGING CENTERS FOR THE STUDY OF MENTAL DISORDER
PA: PA-90-18
P.T. 34; K.W. 0706030, 0705010, 0715129
National Institute on Mental Health
The purpose of this announcement is to establish core resource Centers
dedicated to multidisciplinary research using Positron Emission Tomography
(PET) methodology in conjunction with other existing brain imaging
technologies. The Center Grant will provide support for purchasing the
necessary equipment to establish a PET capability or, where such capability
already exists, support will be provided to assure access to such equipment by
mental health researchers.
Applications may be submitted by any public or private, nonprofit or
for-profit organization, including units of State and local governments.
Women and minority investigators are especially encouraged to apply.
NIH GUIDE - Vol. 19, No. 24, June 29, 1990 - Page 2
Applicants are urged to consider the inclusion of minorities and women in
study populations for all research efforts. If they are not to be included, a
clear rationale for their exclusion should be provided.
It is estimated that approximately $5 million will be available to support
approximately two new grants under this announcement in fiscal year 1991. The
exact amount will depend on appropriated funds, the quality of proposals, and
program priorities at the time of the award.
Applications will be assigned following the usual PHS referral guidelines.
To qualify for fiscal year 1991 funding, applications must be submitted by
October 1, 1990. In subsequent years, a similar timetable will be in effect,
using the October 1 receipt date.
Prior to submission, applicants are encouraged to contact:
Henry Khachaturian, Ph.D.
Neuroimaging and Applied Neuroscience Research Branch
Division of Basic Brain and Behavioral Sciences
National Institute of Mental Health
Room 11-105, Parklawn Building
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-3948
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD
BUILDING IS:
5333 Westbard Avenue
Bethesda, Maryland 20816
NIH GUIDE - Vol. 19, No. 24, June 29, 1990 - Page 3
REQUEST FOR APPLICATIONS (RFA) FOR SMALL (R03) RESEARCH
GRANTS
RFA NUMBER: CA-90-18
DCBDC Small Research Grants on Animal Models of
Solid Tumors
P.T. 34; K.W. 0715035, 0755020, 0710070
NATIONAL CANCER INSTITUTE
LETTER OF INTENT RECEIPT DATE: September 1, 1990
APPLICATION RECEIPT DATE: October 10, 1990
INTRODUCTION
The Cancer Immunology Branch of the Division of Cancer
Biology, Diagnosis, and Centers (DCBDC) of the National
Cancer Institute (NCI) invites applications for small grants
to develop and establish animal models of solid tumors of
non-hemopoietic origin to improve our understanding of the
complexities of the human immune response to these tumors.
Models are sought which demonstrate similar biological
characteristics to human cancer, and which could be used in
future studies to analyze the immunobiology of host-tumor
interactions. This Request for Applications (RFA)
announcement is for a single
solicitation with a specified deadline (October 10, 1990) for
receipt of applications. A maximum of ten awards will be
made if meritorious applications and funds are available.
BACKGROUND INFORMATION
The Cancer Immunology Branch supports a wide range of basic
research on the biology of the immune response to tumors.
Understanding the effects of the changes in tumor cells (from
preneoplastic to neoplastic to metastatic stages) on the
subsequent immune response is a major goal of the Immunology
Program of the NCI. Many advances have been made in
elucidating the complex biology of lymphocyte functions in
the recognition of Self versus non-Self. Further, new mouse
strains have been developed which provide new tools for the
immunologist to unravel the complexities of host-tumor
interaction. However, the limiting feature that restricts
the growth of research in host-tumor interactions is the lack
of well characterized animal models of solid tumors.
New and/or better characterized animal models are required in
order to apply new immunologic research findings to relevant
studies of solid tumors. Deficiencies in our knowledge
exist, some of which can only be addressed in vivo. Little
is known regarding the ongoing immune response during the
natural evolution of tumors. The effective immune response
may differ depending on the stage of disease, and it is important
to know the types and subsets of immune cells which have
potential to eliminate tumor cells at the various stages of
tumor growth and spread. Human tumors have usually
progressed past the early stages when detected clinically
and cannot be studied serially in any case. A model offers
the opportunity to study the interaction of host with tumor
at all stages of growth. Also, clinicians need models that
are more predictive of the clinical situation in order to conduct
basic research leading to immunotherapy of solid tumors in
humans. Animal models relevant to human cancer are needed to
provide basic scientific information that is necessary as a
foundation upon which new or improved immunotherapy
approaches and cancer vaccine development can be based.
In order to advance our understanding of the immunobiology of
solid tumors, NCI has determined that there is a need to
promote the development and production of new animal models
of solid tumors and to encourage the further immunologic
analysis of existing models. The ultimate goal is to obtain
a better understanding of the ongoing immune response to
preneoplastic, neoplastic and metastatic lesions in systems
that demonstrate the biological characteristics of human
tumors.
RESEARCH GOALS AND SCOPE
The goal of this initiative is to provide funds for the
development of new, or further characterization of existing,
animal models of solid tumors of non-hematopoietic origin
which are relevant to human cancer. The initiative is not
limited to small laboratory animals (e.g., mice); however,
appropriate reagents must be available for the immunologic
study of any animal model proposed. These reagents include,
but are not limited to, antibodies to identify and isolate
lymphocyte subsets, macrophages, etc. so that cells of the
immune system can be analyzed in their response to the solid
tumor. Animal models which utilize congenitally athymic
(nude) mice where human tumors are injected subcutaneously
into these mice primarily for maintaining the tumor will be
excluded from review, and those applications will be returned
to the applicant.
The scope of this initiative may comprise the use of
transgenic animals, mice with the severe combined
immunodeficiency (SCID) defect, spontaneously arising tumors,
transplantable tumors from the site of origin to the same
site within the recipient, or other tumor systems developed
by the applicant. Tumors induced by chemicals, viruses or
radiation will be considered if the tumor type exhibits
characteristics analogous to a human tumor. The tumor model
proposed should have a high frequency of tumor incidence, be
genetically stable and relatively easy to maintain. Further,
the animals used in the model must be made available to the
scientific community if the system shows promise for further
investigation.
MECHANISM OF SUPPORT
Support of this program will be through the National
Institutes of Health (NIH) grant-in-aid. Applicants will be
responsible for the planning, direction, and execution of the
proposed project. Except as otherwise stated in this
RFA, awards will be administered under PHS
policy as stated in the Public Health Service Grants Policy
statement, DHHS Publication No. (OASH) 82-50,000, revised
January 1, 1987.
The small grants (R03) mechanism provides research support
specifically limited in time and amount for studies in
categorical program areas. Small grants provide flexibility
for initiating studies, which are generally for preliminary
short-term projects and are non-renewable. Furthermore, the
time interval from application to funding is shortened under
the R03 mechanism, thus allowing new ideas to be investigated
or pursued in a more expeditious manner.
This RFA is a one-time solicitation. Applications received
after the deadline for the receipt date will be returned.
Grants made under this mechanism are non-renewable.
Approximately $700,000 in total costs per year for three
years will be committed specifically to fund applications
which are submitted in response to this RFA. The total
direct costs per application may not exceed $50,000 per year.
It is anticipated that approximately 10 awards will be made.
This funding level is dependent on the receipt of a
sufficient number of applications of high scientific merit.
The total project period for applications submitted in
response to this RFA should be at least one (1)
year and may not exceed two (2) years. The earliest
feasible start date will be April 1,
1991. However, the award date may be delayed to as late as
September 1, 1991. Although this program is provided for in
the financial plans of the NCI,
the award of grants pursuant to this RFA is also contingent
upon the availability of funds for this purpose.
ELIGIBILITY REQUIREMENTS
Non-profit and for-profit organizations and institutions are
eligible to apply.
This RFA is intended for the development of specific new
research areas. These awards may be used to complement an
existing source of support if the studies proposed add a new
dimension (e.g., immunologic or biologic characterization of
model), but may NOT be used to supplement research projects
currently supported by Federal or non-Federal funds or to
provide interim support of projects under review by the PHS.
Existing sources of funding must be thoroughly documented in
the application. Applications without this documentation
will be returned to the applicant without further review.
REVIEW PROCEDURES AND CRITERIA
REVIEW PROCEDURE
Upon receipt, applications will be reviewed by the Division
of Research Grants (DRG) for
completeness. Incomplete applications will be returned to
the applicant without further consideration. Applications
will be evaluated by NCI Program Staff to determine whether
they are responsive to the program requirements and criteria
stated in this RFA. Applications which are judged
non-responsive will be returned to the applicant. Questions
concerning the responsiveness of proposed research to the RFA
should be directed to the program staff named below.
In cases where the number of applications is large compared
to the number of awards to be made, the NIH will conduct a
preliminary scientific peer review to eliminate those which
clearly are not competitive. The NIH will administratively
withdraw from competition those applications judged to be
non-competitive and notify the applicant and institutional
business official.
Those applications judged to be both competitive and
responsive will be further evaluated, using the review
criteria stated below, for scientific and technical merit by
an appropriate peer review group convened by the Division of
Extramural Activities, NCI. The second level of review by
NCI Program Staff considers the application in light of the
special needs of the Institute and the priorities of the
National Cancer Program.
REVIEW CRITERIA
The factors considered in evaluating the scientific merit of
each response to this RFA will be:
o The potential usefulness of the proposed model for
providing new information regarding the immune response to
solid tumors.
o The relevance of the system as a model of human cancer.
o Originality of the research from a scientific and
technical viewpoint.
o Feasibility of research and adequacy of study design.
o Experience, training, time commitment and research
competence of the investigators involved.
o Adequacy of available facilities.
o Provision for the adequate protection of human subjects
and the humane treatment of animals.
The review group will critically examine the submitted budget
and will recommend an appropriate budget for each approved
application.
METHOD OF APPLYING
The PHS research grant application form PHS-398 (revised
10/88) must be used in applying for these grants. These
forms are available at most institutional business offices;
from the Office of Grant Inquiries, Division of Research
Grants, National Institutes of Health, Room 449, Westwood
Building, 5333 Westbard Avenue, Bethesda, MD 20892; or from
the NCI Program Director named below.
The RFA label contained in the 10/88 revision of Application
Form 398 must be affixed to the bottom of the face page.
Failure to use this label could result in delayed processing
of the application such that it may not reach the review
committee in time for review. In addition, the RFA number
and title (to the extent that space permits) should be typed
on line 2 of the face page of the application form.
Submit a signed, typewritten original of the application,
including the Checklist, and four (4) signed, clear, exact
photocopies in one package to the Division of Research
Grants at the address below.
DIVISION OF RESEARCH GRANTS
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**
At the time of submission, two (2) additional copies of the
application should also be sent to:
REFERRAL OFFICER
Division of Extramural Activities
National Cancer Institute
Westwood Building, Room 838
5333 Westbard Avenue
Bethesda, MD 20892
If the applicant has an approved assurance covering the
research (multiple project assurance for human subjects/
full assurance of compliance for animal subjects), the
applicant should provide with the application, certification
of institutional review board (IRB) approval if humans are
involved and verification of the institutional animal care
and use committee (IACUC) approval if animals are involved.
These reviews and approvals should occur PRIOR TO SUBMISSION
of the application for award and the certifications and
verifications should be SUBMITTED WITH the application.
Failure to provide required certifications and verifications
within applications could result in deferral or rejection. If
animals or humans will be subjects of the research at
PERFORMANCE SITES OTHER THAN THE APPLICANT ORGANIZATION, the
applicants must identify, within the application, the
assurance status of each participant. Failure to provide
this information within applications could result in deferral
or rejection.
Applications must be received by October 10, 1990. If an
application is received after the indicated date, it will be
returned. Also, the DRG will
not accept any application in response to this announcement
that is the same as one currently being considered by any
other NIH awarding unit.
LETTER OF INTENT
Prospective applicants are asked to submit by September 1,
1990, a letter of intent to the Program person listed below
that includes a descriptive title of the proposed
research, the name and address of the principal investigator,
the names of other key personnel, the participating
institution, the number and title of the RFA in response to
which the application is being submitted.
Although a letter of intent is not required, is not binding,
and does not enter into the review of subsequent
applications, the information which it contains is extremely
helpful in planning for the review of applictions and allows
NCI staff to estimate the potential review workload.
CONSULTATION WITH PROGRAM STAFF
Prospective applicants are strongly encouraged to discuss
their ideas with Program staff (see below) to determine
whether they fit the definition and guidelines of this
announcement. Applications which, in the opinion of staff,
do not meet these objectives, scope and eligibility criteria
will be returned without review. For further information,
prospective applicants should contact:
DR. JOHN F. FINERTY
Program Director
Cancer Immunology Branch
National Cancer Institute
National Institutes of Health
Executive Plaza South, Room 634
6120 Executive Boulevard
Rockville, MD 20892
Telephone 30l-496-78l5
FAX: 30l-496-8656
This program is described in the Catalog of Federal Domestic
Assistance No.13.396. Awards are under authorization of the
Public Health Service Act, Title, IV, Part A (Public Law
78-410, as amended by Public Law 99-158, 42 USC 241 and 285)
and administered under PHS grant policies and Federal
Regulations 42 CFR 52 and 45 CFR Part 74. This program is
not subject to the intergovernmental review requirements of
Executive order 12372 or Health Systems Agency review.